checkAd

EQS-News Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100(TM) (aviptadil) - Seite 2

Nachrichtenquelle: EQS Group AG
10.02.2021, 07:00  |  154   |   |   

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

www.relieftherapeutics.com

CONTACT:
RELIEF THERAPEUTICS Holding AG

Raghuram (Ram) Selvaraju, Ph.D., MBA                    
Chairman of the Board
Mail: contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:
MC Services AG

Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of respiratory failure from COVID-19. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


End of Media Release


Language: English
Company: RELIEF THERAPEUTICS Holdings AG
Avenue de Sécheron 15
1202 Genève
Switzerland
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Listed: SIX Swiss Exchange
EQS News ID: 1167259
Seite 2 von 3
RELIEF THERAPEUTICS Holding Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de






0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

EQS-News Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100(TM) (aviptadil) - Seite 2 EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100(TM) (aviptadil) 10.02.2021 / 07:00 Relief Confirms Release of Preliminary Findings …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

ZeitTitel
04.05.21
04.05.21
04.05.21
22.04.21
22.04.21
19.04.21
19.04.21
19.04.21
15.04.21
15.04.21